1. Patients with lymphatic malformations who receive the immunostimulant OK‐432 experience excellent long‐term outcomes. (14th July 2015) Authors: Ghaffarpour, N; Petrini, B; Svensson, LA; Boman, K; Wester, T; Claesson, G Journal: Acta pædiatrica Issue: Volume 104:Number 11(2015:Nov.) Page Start: 1169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗